Latest News Archive

Please select Category, Year, and then Month to display items

UFS contributes to discussion on food integrity, animal welfare, and antibiotics

03 May 2021 | Story Leonie Bolleurs | Photo Sonia Small

Prof Robert Bragg from the Department of Microbiology and Biochemistry at the University of the Free State formed part of a live panel discussion with leaders from the food and beverage sector, debating the challenges facing the industry and sharing their lessons and solutions.

The discussion, part of a week-long virtual event (19-23 April), was attended by more than 1 300 attendees representing 500 food manufacturers, retailers, ingredient companies, and laboratories from 83 countries.

The magazine, New Food, coordinated the initiative that focused on food integrity. Speaking with Prof Bragg at the session that centred around animal welfare, zoonotic disease, and antibiotics, were Catherine McLaughlin, Chair, Responsible Use of Medicines in Agriculture (RUMA); Vicky Bond, UK Managing Director, The Humane League; and Daniela Battaglia, Livestock Development Officer, Food and Agriculture Organization of the United Nations (FAO).

The rise of antibiotic resistance

James Russell, President of the British Veterinary Association (BVA), was the moderator of the discussion that also touched on the issues surrounding animal welfare; how animal welfare can impact meat quality; avoiding future zoonotic disease; the rise of antibiotic resistance; ethical considerations to be mindful of; and the use of pesticides and safety considerations.

Prof Bragg specifically talked about antibiotic resistance. “Mankind has major problems with antibiotics,” he said.

He asked if animal agriculture can be sustained without the use of antibiotics and stated that it was necessary to look at alternatives. Possible solutions he suggested include improved vaccines, bacteriophages, and phage enzymes. He, however, believes that biosecurity will be the most effective alternative.

Living in a post-antibiotic area

Disinfectants are one of the biosecurity measures taken to minimise the risk of infectious diseases. “But it is important to be aware of the fact that as resistance to antibiotics increases the resistance to disinfectants also increases,” said Prof Bragg.

He continued: “An increase in the use of disinfectants increases the resistance to disinfectants. This is also evident in humans, especially now during the COVID-19 pandemic. Much of these disinfectants are also of poor quality,” he said.

According to Prof Bragg, we are living in a post-antibiotic era. “Although food standards are higher in developed countries such as in Europe – where people can pay more for poultry that were fed diets with reduced antibiotics, it is important to keep in mind that people cannot pay the same for poultry in developing countries. These countries often import poultry from countries where the food standards are not that high and where birds were treated to diets containing more antibiotics. A large supplier of poultry in Africa is small-scale farmers, who also feed their birds food containing higher levels of antibiotics.”

“We need to look at the antibiotic problem as a global problem; a concern that will be with us for a while,” said Prof Bragg.

One solution provided by the group was for mankind to reduce its meat intake and moving to a more plant-based diet. This will have a significant effect on animal welfare as well as reducing the demand for antibiotics.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept